Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088)

Antiviral Therapy

Volumn 8, Issue 5, 2003, Pages 427-434

  Vray, Muriel ^a   Meynard, Jean Luc ^b   Dalban, Cécile ^a   Morand Joubert, Laurence ^b   Clavel, François ^c   Brun Vézinet, Françoise ^c   Peytavin, Gilles ^c   Costagliola, Dominique ^a   Girard, Pierre Marie ^b  

^a INSERM   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

ADULT; AGED; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT CARE; PHENOTYPE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARD; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0242331663     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, Chiesi A, Phillips AN, Kirk O & Lundgren JD. AIDS across Europe, 1994-1998: the EuroSIDA study. Lancet 2000; 356(9226):291-296.
2. Palella FJ Jr, Dalaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmerg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study investigators. New England Journal of Medicine 1998; 338:853-860.
3. Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M & Moss A. Provider assessment of adherence to HIV antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2001; 26(5):435-442.
4. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP & Merigan TC. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 16:F83-F93.
5. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F & Girard PM for the Narval Trial Group. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16:727-736.
6. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CAB, Schapiro JM & Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-2199.
7. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C, Clotet B & the Havana Study Group. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-218.
8. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R & De Luca A. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369-379.
9. Baxter JD, Merigan TC, Wentworth DN, Neaton JD, Hoover ML, Hoetelmans RM, Piscitelli SC, Verbiest WH & Mayers DL. Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic response to salvage therapy. AIDS 2002; 16:1131-1138.
10. Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM & Dellamonica P. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000; 14:1333-1339.
11. Duran S, Spire B, Raffi F, Walter V, Bouhour D, Journot V, Cailleton V, Leport C, Moatti JP & the APROCO cohort study group. Self-reported symptoms following initiation of a protease inhibitor-containing regimen: association with adherence to HAART in HIV-infected patients. HIV Clinical Trials 2001; 2:38-45.
12. Shafer RW, Kantor R & Gonzales MJ. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Reviews 2000; 2:211-228.
13. Costagliola D, Descamps D, Calvez V, Masquelier B, Ruffault A, Telles F, Meynard JL & Brun-Vézinet F. Presence of thymidine-associated mutations and response to d4T, abacavir, and ddI in the control arm of the Narval ANRS 088 trial. 8th CROI. Chicago, Ill., USA, February 4-8 2001. Abstract 450.
14. Descamps D, Masquelier B, Mamet JP, Calvez V, Ruffault A, Telles F, Goetschel A, Girard PM, Brun-Vézinet F & Costagliola D. A genotypic sensitivity score for amprenavir based on genotype at baseline and virological response. Antiviral Therapy 2001; 6(Suppl. 1):103.
15. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC & Efron B. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Annals of Internal Medicine 1999; 131:813-821.
16. Race E, Dam E, Obry V, Paulous S & Clavel F. Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies. AIDS 1999; 13:2061-2068.
17. Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcorn TM, Pauwels R, Van Houtte M, Staszewski S, Miller V & Larder BA. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 2000; 14:1203-1210.
18. Dronda F, Casado JL, Moreno S, Hertogs K, Garcia-Arata I, Antela A, Perez-Elias MJ, Ruiz L & Larder B, the Nelsane Study. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene. AIDS Research & Human Retroviruses 2001; 17:211-215.
19. Raguin G, Taburet AM, Chêne G, Morand-Joubert L, Droz C, Le Tiec C, Clavel F & Girard PM, the Puzzle 1 Study Group. Pharmacokinetic parameters and virological response to the combination of lopinavir/ritonavir (LPV/r) and amprenavir (APV) in HIV-infected patients with multiple treatment failures: week-6 results of Puzzle 1-ANRS Study. 9th CROI. Seattle, Wash., USA, February 24-28 2002. Abstract 420
20. Benson CA, Deeks SG, Brun SC, Gulick RM, Eron JJ, Kessler HA, Murphy RL, Hicks C, King M, Wheeler D, Feinberg J, Stryker R, Sax PE, Riddler S, Thompson M, Real K, Hsu A, Kempf D, Japour AJ & Sun E. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. Journal of Infectious Diseases 2002; 185:599-607.
21. Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, Perneger TV, Perrin L, Kaiser L & Yerly S, the Swiss HIV Cohort Study. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 1999; 13:F17-F21.
22. Kessler H, Cohen C, Sension M, Farthing C, Jacobsen S, Conant M, Hertogs K, Verbiest W, Lanier R, Rinehart A & Graham N. Response to abacavir-containing regimens is not affected by presence of pre-existing lamivudine resistance and is greater than response in non abacavir-containing regimens in VIRA 3001. Antiviral Therapy 2000; 5(Suppl. 3):82
23. Lanier ER, Scott J, Steel H et al. Multivariate analysis of predictors of response to ziagen: comparison of prior anti-retroviral therapy, baseline HIV RNA, CD4 count and viral resistance. Antiviral Therapy 1999; 4(Suppl. 1).
24. Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M & Katzenstein DA, the AIDS Clinical Trials group 364 Study Team. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. New England Journal of Medicine 2001; 345:398-407.
25. Falloon J, Ait-Khaled M, Thomas DA, Brosgart CL, Eron JJ Jr, Feinberg J, Flanigan TP, Hammer SM, Kraus PW, Murphy R, Torres R & Masur H, the CNA2007 Study Team. HIV-1 genotype and phenotype correlate with virologic response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS 2002; 16:387-396.
26. Haas DW, Fessel WJ, Delapenha RA, Kessler H, Seekins D, Kaplan M, Ruiz NM, Ploughman LM, Labriola DF & Manion DJ, the Collaborative Protocol 020 Study Group. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind placebo-controlled trial. Journal of Infectious Diseases 2001; 183:392-400.
27. Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, Hermans P, Antunes F, Ledergerber B, Kirk O & Lundgren JD, the EuroSIDA Study Group. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001; 15:2385-2395.
28. Mellors J, Vaida F, Bennett K, Hellmann NS, DeGruttola V & Hammer S for the ACTG 398 Study Team. Efavirenz hypersusceptibility improves virologic response to multidrug salvage regimens in ACTG 398. 9th CROI. Seattle, Wash., USA, February 24-28 2002. Abstract 45.
29. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA, Gu Z, Song Q, Manne J, Islam S, Castriota G & Prasad VR. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996; 271:1282-1285.
30. Picard V, Angelini E, Maillard A, Race E, Clavel F, Chêne G, Ferchal F & Molina JM. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. Journal of Infectious Diseases 2001; 184:781-784.
31. Larder B, Kemp SD & Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-699.